-
08 OctUpon successful commercialization of the diagnostic kit, IPA has committed to paying 5% of Global Net Revenue to the University of Victoria.
... READ MORE -
07 OctDr. Bath will discuss current therapeutics in the clinic, IPA’s Polytope™ therapy and vaccine strategies.
... READ MORE -
-
29 SepAdjusted EBITDA increases to $932,000 compared to a loss of $481,000 for the same period last year.
... READ MORE -
-
25 SepVaccine design was based on large sets of data obtained during the analysis of IPA’s SARS-CoV-2 therapeutic programs.
... READ MORE
Toggle Nav
